Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.

Abstract: Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.

Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.

Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.

Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.

Abstract: Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Abstract: A method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.

Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.

Abstract: The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.

Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Abstract: The present invention relates to antibodies and binding fragments thereof that bind the ?-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.

Abstract: Methods for the ex vivo modification of the surfaces of viable tissue result in tissue modifications that are stable and/or result in the controlled release of active compounds, and are expected to provide effective protection for transplanted tissue subsequent to transplant.

Abstract: Subject matter of the present invention is an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2 for use in a therapy of cancer. Subject matter of the present invention is anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of cancer according to claim 1 wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold requires the presence of a C-terminally amidated tyrosine residue within the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2, for binding.

Abstract: A receiving apparatus includes: a capacitance element connected to a receiving side of a transmission line through which a transmission signal is transmitted, and where a direct current flowing through the transmission line changes in accordance with a logic level of a data signal; a transistor configured to amplify a current flowing between a receiving-side node and a power supply node to which a power supply potential is supplied, where the receiving-side node is positioned between the transmission line and the capacitance element; and a data signal generator configured to generate the data signal based on the current amplified by the transistor.

Abstract: A problem of incomplete inhibition of harmful cells/bacteria and short duration of time, after the photodynamic treatment, during which such cells may re-grow, is solved by exposing the target bacteria with a multi-component photosensitizer material formed by adding a predetermined potentiating chemical to a conventional single-component photosensitizer at the target, prior to irradiating the target with light. The multi-component photosensitizer is effectuated by forming a mix of the two chemical compositions or by sequential exposure of the bacteria to a single-component photosensitizer and the potentiating chemical of choice.

Abstract: Methods are disclosed for tethering a biological entity to a substrate comprising: (a) forming a supported lipid bilayer on a surface of a substrate, wherein the supported lipid bilayer comprises an anchor molecule conjugated to a first affinity tag that is present in the lipid bilayer at a concentration greater than or equal to 5 mole percent; and (b) contacting the supported lipid bilayer with a biological entity, wherein the biological entity comprises an nonlinear-active label and a second affinity tag capable of binding to the first affinity tag, thereby tethering the biological entity to the supported lipid bilayer in an oriented fashion.

Abstract: The present disclosure provides conjugate structures and hydrazinyl-substituted heteroaryl compounds used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates and compounds, as well as methods of using the same.

Abstract: Multitargeted pyrimidine nucleoside carbamates, substituted with fluorine at both the base and the sugar moieties, are disclosed (see Formula I): where R=linear or branched alkyl (C1-7); R?=H, hydroxy protecting group; R?=H, phosphate ester, amino acid alkyl (C1-7) ester phoshoramidate, or phosphorodiamidate. The disclosed compounds are fluoropyrimidine prodrugs that are characterized by a novel combination of structural components that provide intracellular metabolites capable of 1) inhibiting several cellular enzymes required for the synthesis and proper functioning of DNA, and 2) causing DNA damage by misincorporation into DNA. By acting on multiple targets with different mechanisms of action, compounds of Formula I reduce the likelihood of the emergence of drug resistance, a major drawback of the use of nucleoside-based anticancer and antiviral drugs.

Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.

Abstract: The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

Abstract: A computer-implemented method includes: receiving, by a computing device, information regarding a range in which an Internet-of-Things (IoT) network is to be implemented; determining, by the computing device, respective detection scores for a plurality of IoT devices for each of a plurality of proposed congregation of IoT devices; determining, by the computing device, a minimum number of the plurality of IoT devices to cover the range by incorporating the detection scores into a covariance model; and outputting, by the computing device, information identifying the minimum number of the plurality of IoT devices for designing the IoT network.

Abstract: The present invention relates to a method for producing a lysine carboxylase mutant strain, characteristics of the mutant strain, a gene encoding the lysine decarboxylase mutant strain, and a method for producing cadaverine using the same. The present invention provides lysine decarboxylase derived from E. coli improved through a protein engineering variation. In addition, the lysine decarboxylase mutant strain of the present invention increases activity, pH stability, and thermal stability at the time of producing cadaverine, thereby reducing production costs, through increasing a yield and productivity.

Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.

Abstract: A kit and method for evaluation of the quality and the operating parameters of any types of fully automated open ELISA instruments are disclosed. The kit and method can be used to reliably assess quality control parameters including precision, volume removal accuracy, plate reader accuracy, plate reader linearity, plate washer quality, drift absence, and carryover absence. The evaluation can be completed in a timely and cost-effective manner and provide laboratories with the ability to readily validate the operation and performance of a fully automated ELISA instrument.

Abstract: This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.

Abstract: The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.

Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Abstract: A method is provided for the poly signal activation of apoptosis of malignant solid tumour cells, carried out by means of the targeted delivery of thallium salts by surface-modified MS2 phage virions, which contain a cyclic iRGD ligand that has a high affinity for the integrins avb3 and avb5 and is covalently bound with the shell and with the core, which contains genomic RNA and thallium salts. Complex, efficient, prolonged cytotoxic action is provided on focal and metastatic clusters of malignant solid tumour cells, while minimizing undesirable side effects on the healthy cells of an organism.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.

Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).

Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.

Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.